Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "A-type amino acid transporter" is a non-standard and ambiguous designation. It most commonly refers to members of the solute carrier (SLC) family involved in neutral amino acid transport, such as ASCT2 (SLC1A5). ASCT2 is a neutral amino acid transporter primarily responsible for glutamine uptake and amino acid pool harmonization, playing significant roles in cancer and cell metabolism. The term might also implicitly refer to heteromeric amino acid transporters like b(0,+)AT1-rBAT (SLC7A9/SLC3A1), which is crucial for the reabsorption of cystine and dibasic amino acids, and whose dysfunction leads to cystinuria. Both ASCT2 and b(0,+)AT1-rBAT are recognized therapeutic targets, particularly in oncology, metabolic disorders, and inherited diseases. The ambiguous "A-type" designation should always be clarified by using the specific canonical target names for accurate scientific and clinical communication.
Competitive inhibition of amino acid transport, blockade of substrate binding pocket, disruption of transporter trafficking or maturation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alanine, Serine, Cysteine Transporter 2 (ASCT2).